ES2482168T3 - Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente - Google Patents
Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente Download PDFInfo
- Publication number
- ES2482168T3 ES2482168T3 ES08013741.7T ES08013741T ES2482168T3 ES 2482168 T3 ES2482168 T3 ES 2482168T3 ES 08013741 T ES08013741 T ES 08013741T ES 2482168 T3 ES2482168 T3 ES 2482168T3
- Authority
- ES
- Spain
- Prior art keywords
- opioids
- patients
- treatment
- resistant cancer
- methadone group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Uso de opioides del grupo de la metadona capaces de inhibir la proliferación de células cancerosas para la preparación de un fármaco para el tratamiento de pacientes con cáncer resistente
Description
Claims (1)
-
imagen1
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08013741.7A EP2149372B1 (en) | 2008-07-31 | 2008-07-31 | Use of opioids of the methadone group for the treatment of resistant cancer patients |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2482168T3 true ES2482168T3 (es) | 2014-08-01 |
Family
ID=40011012
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08013741.7T Active ES2482168T3 (es) | 2008-07-31 | 2008-07-31 | Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente |
ES09776348.6T Active ES2596363T3 (es) | 2008-07-31 | 2009-01-29 | Opioides para su uso en el tratamiento de pacientes con cáncer resistente |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09776348.6T Active ES2596363T3 (es) | 2008-07-31 | 2009-01-29 | Opioides para su uso en el tratamiento de pacientes con cáncer resistente |
Country Status (13)
Country | Link |
---|---|
US (1) | US8901175B2 (es) |
EP (2) | EP2149372B1 (es) |
JP (1) | JP5804945B2 (es) |
CN (1) | CN102159212B (es) |
BR (1) | BRPI0916555B1 (es) |
CA (1) | CA2732497C (es) |
DK (2) | DK2149372T3 (es) |
ES (2) | ES2482168T3 (es) |
HU (1) | HUE031337T2 (es) |
PL (2) | PL2149372T3 (es) |
PT (2) | PT2149372E (es) |
RU (1) | RU2520636C2 (es) |
WO (1) | WO2010012319A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
PL2716291T3 (pl) | 2012-10-08 | 2020-06-15 | Universität Ulm | Połączenie opioidów i leków przeciwnowotworowych do leczenia nowotworów |
AU2018351502A1 (en) * | 2017-10-20 | 2020-03-26 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
WO2019197015A1 (en) | 2018-04-09 | 2019-10-17 | Peter Truog | Composition comprising 4-phenylbutyric acid derivatives & opioids |
CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
WO2020239948A1 (en) | 2019-05-28 | 2020-12-03 | Isanas Ag | A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173486A (en) * | 1991-08-26 | 1992-12-22 | Bristol-Myers Squibb Company | Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents |
DK1885187T3 (da) * | 2005-05-13 | 2013-12-09 | Novartis Ag | Fremgangsmåde til behandling af lægemiddelresistent cancer |
-
2008
- 2008-07-31 DK DK08013741.7T patent/DK2149372T3/da active
- 2008-07-31 ES ES08013741.7T patent/ES2482168T3/es active Active
- 2008-07-31 PT PT80137417T patent/PT2149372E/pt unknown
- 2008-07-31 PL PL08013741T patent/PL2149372T3/pl unknown
- 2008-07-31 EP EP08013741.7A patent/EP2149372B1/en active Active
-
2009
- 2009-01-29 CN CN200980136278.9A patent/CN102159212B/zh active Active
- 2009-01-29 PL PL09776348T patent/PL2320900T3/pl unknown
- 2009-01-29 HU HUE09776348A patent/HUE031337T2/hu unknown
- 2009-01-29 CA CA2732497A patent/CA2732497C/en active Active
- 2009-01-29 ES ES09776348.6T patent/ES2596363T3/es active Active
- 2009-01-29 JP JP2011520333A patent/JP5804945B2/ja active Active
- 2009-01-29 WO PCT/EP2009/000584 patent/WO2010012319A1/en active Application Filing
- 2009-01-29 RU RU2011107280/15A patent/RU2520636C2/ru active
- 2009-01-29 EP EP09776348.6A patent/EP2320900B1/en active Active
- 2009-01-29 US US13/056,918 patent/US8901175B2/en active Active
- 2009-01-29 PT PT97763486T patent/PT2320900T/pt unknown
- 2009-01-29 BR BRPI0916555-0A patent/BRPI0916555B1/pt active IP Right Grant
- 2009-01-29 DK DK09776348.6T patent/DK2320900T3/en active
Also Published As
Publication number | Publication date |
---|---|
EP2149372A1 (en) | 2010-02-03 |
CA2732497C (en) | 2017-01-17 |
RU2011107280A (ru) | 2012-09-10 |
BRPI0916555A2 (pt) | 2015-11-10 |
EP2320900B1 (en) | 2016-07-06 |
PT2320900T (pt) | 2016-10-13 |
US8901175B2 (en) | 2014-12-02 |
CN102159212B (zh) | 2015-09-16 |
RU2520636C2 (ru) | 2014-06-27 |
CA2732497A1 (en) | 2010-02-04 |
DK2149372T3 (da) | 2014-07-07 |
BRPI0916555B1 (pt) | 2021-06-29 |
HUE031337T2 (hu) | 2017-07-28 |
WO2010012319A1 (en) | 2010-02-04 |
US20110270011A1 (en) | 2011-11-03 |
ES2596363T3 (es) | 2017-01-09 |
PL2149372T3 (pl) | 2015-03-31 |
DK2320900T3 (en) | 2016-10-24 |
CN102159212A (zh) | 2011-08-17 |
EP2320900A1 (en) | 2011-05-18 |
EP2149372B1 (en) | 2014-04-02 |
PT2149372E (pt) | 2014-07-25 |
JP2011529454A (ja) | 2011-12-08 |
JP5804945B2 (ja) | 2015-11-04 |
PL2320900T3 (pl) | 2017-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2575397T3 (es) | Uso de péptidos natriuréticos para el tratamiento de síndromes de angioedema | |
ES2502472T3 (es) | Composición adhesiva para su uso en un inmunosensor | |
ES2482168T3 (es) | Uso de opioides del grupo de la metadona para el tratamiento de pacientes con cáncer resistente | |
CL2009000545A1 (es) | Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer. | |
ES2496092T3 (es) | El uso de amisulprida para tratar náuseas y vómitos posoperatorios | |
ES2665917T3 (es) | Endoxifeno para su uso en el tratamiento del cáncer | |
CL2011003229A1 (es) | Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer. | |
CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
CL2011001255A1 (es) | Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
CL2009000542A1 (es) | Uso de un antagonista de c-met y egfr de formula general i para preparar un medicamento para tratar el cancer. | |
CO6640285A2 (es) | 5-alquinil-pirimidinas | |
CL2009000447A1 (es) | Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf. | |
CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
PA8740901A1 (es) | Compuestos organicos | |
CL2011001232A1 (es) | Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer | |
CR20110340A (es) | Compuestos purina | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
CL2008003200A1 (es) | Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon. | |
ES2527454T3 (es) | El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico | |
CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. |